Somatropin for treating AIDS-related wasting syndrome

American Journal of Health-System Pharmacy

Volumn 54, Issue 22, 1997, Pages 2618-2620

  Kakuda, Thomas N ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; DRONABINOL; HUMAN GROWTH HORMONE; IMMUNOMODULATING AGENT; MEGESTROL ACETATE; NANDROLONE; OXANDROLONE; SOMATOMEDIN C; STANOZOLOL; TESTOSTERONE; THALIDOMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CACHEXIA; CLINICAL TRIAL; DRUG EFFECT; ENTERIC FEEDING; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PARENTERAL NUTRITION; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 0030771676     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.22.2618     Document Type: Short Survey

References (22)

1. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR. 1987; 36(suppl 1):3S-15S.
2. Weinroth SE, Parenti DM, Simon GL. Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis. 1995; 4:76-94.
3. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr. 1985; 42:1255-65.
4. Kotler DP, Tierney AR, Wang J et al. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989; 50:444-7.
5. Grunfeld C. What causes wasting in AIDS? N Engl J Med. 1995; 333:123-4.
6. Von Roenn JH, Knopf K. Anorexia/cachexia in patients with HIV: lessons for the oncologist. Oncology. 1996; 10:1049-56.
7. Serono Serostim hGH approved Aug. 23 for AIDS wasting. FDC Rep. 1996; 58(Aug 26):T&G 1.
8. Serostim package insert. Randolph, MA: Serpno Laboratories; 1996 Jul.
9. Hebel SK, ed. Drug facts and comparisons. St. Louis: Facts and Comparisons; 1995:116-116c.
10. Krentz AJ, Koster FT, Grist DM et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-associated complex. J Acquir Immune Defic Syndr. 1993; 6:245-51.
11. Mulligan K, Grunfeld C, Hellerstein MK et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab. 1993; 77:956-62.
12. Schambelan M, Mulligan K, Grunfeld C et al. Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med. 1996; 125:873-82.
13. Pinto G, Brauner R, Goulet O et al. Recombinant human growth hormone therapy for cachexia in HIV infected children. Paper presented at Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 26.
14. Rodgers BD. Catabolic hormones and growth hormone resistance in acquired immunodeficiency syndrome and other catabolic states. Proc Soc Exp Biol Med. 1996; 212:324-31.
15. Mantzoros CS, Moses AC. Whither recombinant human growth hormone? Ann Intern Med. 1996; 125:932-4.
16. Reyes-Terán G, Sierra-Madero JG, Martínez del Cerro V et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996; 10:1501-7.
17. Waters D, Danska J, Hardy K et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. Ann Intern Med. 1996; 125:865-72.
18. Laurence J, Grimison B, Gonenne A. Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro. Blood. 1992; 79:467-72.
19. Serono Serostim responders should be identified from data, FDA joint cmte. says: votes 8-7 against approval of somatropin hGH for AIDS wasting. FDC Rep. 1996; 58(Mar 11):17-8.
20. Recombinant human growth hormone. Med Lett Drugs Ther. 1994; 36:77-8.
21. Steele FR. Growth hormone and AIDS-related wasting. Nat Med. 1996; 2:369-70.
22. Serostim treatment guidelines. Randolph, MA: Serono Laboratories; 1996 Sep.